Advertisement
AMRX vs HROW
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AMRX is a StrongBuy and HROW is a StrongBuy.
AMRX in +5.20% Uptrend, growing for three consecutive days on October 27, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where AMRX advanced for three days, in 245 of 299 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 21, 2026. You may want to consider a long position or call options on AMRX as a result. In 65 of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 77%.
The Moving Average Convergence Divergence (MACD) for AMRX just turned positive on October 23, 2026. Looking at past instances where AMRX's MACD turned positive, the stock continued to rise in 36 of 44 cases over the following month. The odds of a continued upward trend are 82%.
Bearish Trend Analysis
The 10-day RSI Indicator for AMRX moved out of overbought territory on October 28, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 44 similar instances where the indicator moved out of overbought territory. In 30 of the 44 cases, the stock moved lower in the following days. This puts the odds of a move lower at 68%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AMRX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 68%.
AMRX broke above its upper Bollinger Band on October 26, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 6 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. AMRX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 100 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: AMRX's P/B Ratio (225.173) is very high in comparison to the industry average of (8.542). P/E Ratio (42.700) is within average values for comparable stocks, (-1.854). Projected Growth (PEG Ratio) (1.947) is also within normal values, averaging (2.152). Dividend Yield (0.000) settles around the average of (0.046) among similar stocks. P/S Ratio (1.899) is also within normal values, averaging (178.797).
HROW's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for HROW turned positive on October 20, 2026. Looking at past instances where HROW's MACD turned positive, the stock continued to rise in 39 of 47 cases over the following month. The odds of a continued upward trend are 83%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where HROW's RSI Indicator exited the oversold zone, 32 of 41 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 78%.
The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on HROW as a result. In 67 of 81 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 83%.
Following a +1.52% 3-day Advance, the price is estimated to grow further. Considering data from situations where HROW advanced for three days, in 239 of 292 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
HROW may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where HROW declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 79%.
The Aroon Indicator for HROW entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 63 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock slightly better than average.
The Tickeron Price Growth Rating for this company is 78 (best 1 - 100 worst), indicating slightly worse than average price growth. HROW’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 87 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: HROW's P/B Ratio (73.965) is slightly higher than the industry average of (8.801). P/E Ratio (-30.293) is within average values for comparable stocks, (-2.500). Projected Growth (PEG Ratio) (0.270) is also within normal values, averaging (2.152). Dividend Yield (0.000) settles around the average of (0.044) among similar stocks. P/S Ratio (4.627) is also within normal values, averaging (178.797).
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
AMRX | HROW | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 32 | 11 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 100 Overvalued | 87 Overvalued | |
PROFIT vs RISK RATING 1..100 | 6 | 63 | |
SMR RATING 1..100 | 99 | 99 | |
PRICE GROWTH RATING 1..100 | 36 | 78 | |
P/E GROWTH RATING 1..100 | 97 | 14 | |
SEASONALITY SCORE 1..100 | 50 | 85 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
HROW's Valuation (87) in the Pharmaceuticals Other industry is in the same range as AMRX (100) in the Pharmaceuticals Major industry. This means that HROW’s stock grew similarly to AMRX’s over the last 12 months.
AMRX's Profit vs Risk Rating (6) in the Pharmaceuticals Major industry is somewhat better than the same rating for HROW (63) in the Pharmaceuticals Other industry. This means that AMRX’s stock grew somewhat faster than HROW’s over the last 12 months.
AMRX's SMR Rating (99) in the Pharmaceuticals Major industry is in the same range as HROW (99) in the Pharmaceuticals Other industry. This means that AMRX’s stock grew similarly to HROW’s over the last 12 months.
AMRX's Price Growth Rating (36) in the Pharmaceuticals Major industry is somewhat better than the same rating for HROW (78) in the Pharmaceuticals Other industry. This means that AMRX’s stock grew somewhat faster than HROW’s over the last 12 months.
HROW's P/E Growth Rating (14) in the Pharmaceuticals Other industry is significantly better than the same rating for AMRX (97) in the Pharmaceuticals Major industry. This means that HROW’s stock grew significantly faster than AMRX’s over the last 12 months.
| AMRX | HROW | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 68% | 2 days ago 78% |
| Stochastic ODDS (%) | 1 day ago 77% | 2 days ago 80% |
| Momentum ODDS (%) | 1 day ago 77% | 2 days ago 83% |
| MACD ODDS (%) | 1 day ago 82% | 2 days ago 83% |
| TrendWeek ODDS (%) | 1 day ago 84% | 2 days ago 79% |
| TrendMonth ODDS (%) | 1 day ago 83% | 2 days ago 83% |
| Advances ODDS (%) | 3 days ago 82% | 2 days ago 82% |
| Declines ODDS (%) | 16 days ago 68% | 16 days ago 79% |
| BollingerBands ODDS (%) | 1 day ago 65% | 2 days ago 75% |
| Aroon ODDS (%) | N/A | 2 days ago 85% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AMRX’s FA Score shows that 1 FA rating(s) are green while HROW’s FA Score has 1 green FA rating(s).
- AMRX’s FA Score: 1 green, 4 red.
- HROW’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AMRX’s TA Score shows that 3 TA indicator(s) are bullish while HROW’s TA Score has 5 bullish TA indicator(s).
- AMRX’s TA Score: 3 bullish, 4 bearish.
- HROW’s TA Score: 5 bullish, 3 bearish.
Price Growth
AMRX (@Pharmaceuticals: Generic) experienced а +4.25% price change this week, while HROW (@Pharmaceuticals: Generic) price change was +6.54% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +0.24%. For the same industry, the average monthly price growth was -9.52%, and the average quarterly price growth was +5.69%.
Reported Earning Dates
AMRX is expected to report earnings on Nov 03, 2026.
HROW is expected to report earnings on Nov 09, 2026.
Industries' Descriptions
@Pharmaceuticals: Generic (+0.24% weekly)A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.
Advertisement
HROW and
Correlation & Price change
A.I.dvisor indicates that over the last year, HROW has been loosely correlated with AQST. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if HROW jumps, then AQST could also see price increases.
| Ticker / NAME | Correlation To HROW | 1D Price Change % | ||
|---|---|---|---|---|
| HROW | 100% | +1.10% | ||
| AQST - HROW | 34% Loosely correlated | +3.93% | ||
| AMRX - HROW | 30% Poorly correlated | -1.40% | ||
| RMTI - HROW | 27% Poorly correlated | +6.56% | ||
| AYTU - HROW | 27% Poorly correlated | +3.68% | ||
| TEVA - HROW | 27% Poorly correlated | -1.04% | ||
More | ||||